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During the last decade, in-hospital programs for patients under-
going total hip replacement (THA) and total knee replacement 
(TKA) have changed dramatically from (1) staying in bed for 
1–3 days on epidural pain treatment followed by mobilization 
on crutches for weeks including several restrictions in daily 
activities, to (2) mobilization a few hours after surgery, with 
no restrictions in daily activities and no more than 2–4 days in 
hospital (Kerr and Kohan 2008, Husted et al. 2011, Malviya 
et al. 2011). This change has been possible due to optimized 
opioid-sparing multimodal analgesia protocols together with 
local infiltration analgesia techniques, and a detailed educa-
tion of the patients before, during, and after the operation.
In that same period, evidence-based guidelines from the 
American College of Chest Physicians recommended phar-
macological prophylaxis after THA and TKA for at least 10 
days but preferably up to 35 days (Geerts et al. 2008). This 
recommendation is mainly based on randomized studies 
comparing current and new low-molecular-weight heparins 
(LMWH) and other anticoagulatory agents with a primary 
efficacy outcome on deep-vein thrombosis (DVT) including 
the non-symptomatic cases found by venography (Eriksson 
et al. 2008, Kakkar et al. 2008, Turpie et al. 2009, Lassen et 
al. 2010a, b). These authors did not state when their patients 
were mobilized after surgery, or for how many hours a day 
they were mobilized—factors that are known to have major 
importance in the development of DVT. However, some of the 
reports described a hospital stay of between 8 and 12 days 
(Turpie et al 2009, Lassen et al. 2010a, b), suggesting slow 
mobilization of patients.
Furthermore, there have been reports of a possible risk 
of complications when patients are treated with long-term 
thromboprophylaxis, complications such as wound oozing, 
bleeding, or deep infection (Jameson et al. 2010). It is there-
fore important to treat patients for the shortest period possi-
ble to prevent symptomatic DVT and pulmonary embolism, 
but probably not the asymptomatic and more frequent DVT, 
although the latter requires further evaluation. Orthopedic 
surgeons worldwide have questioned whether we must treat 
our joint replacement patients for such long periods as recom-
mended, and there is an open debate on how to create national 
guidelines for DVT prophylaxis after major joint replacement 
and other procedures (Davies and Rayment 2010, Polk and 
Qadan 2010, Treasure et al. 2010, Kakkar and Rushton-Smith 
2011, Qadan et al. 2011, Poultsides et al. 2012).
There is an urgent need for randomized studies of today’s 
fast-track joint replacement patients, to determine whether 
they really need DVT prophylaxis, and if so, the shortest time 
required for prophylaxis. Such data might save billions of 
dollars for our national health systems and prevent patients 
from being treated for an unnecessarily long time. However, 
the industry that has supported the current trials (Eriksson et 
al. 2008, Kakkar et al. 2008, Turpie et al. 2009, Lassen et al. 
2010a, b, Lee et al. 2012) will probably neither sponsor nor 
initiate such studies, for obvious reasons. 
In the meantime, we await information from a prospective, 
large Danish cohort study involving 5,000 fast-track THA and 
TKA patients with prophylaxis only during the short period 
in hospital (2–4 days). The results will be analyzed in early 
2012. However, preliminary data suggest that there is no need 
for prolonged prophylaxis in a fast-track setting (Husted et al. 
2010) or with early mobilization (Chandrasekaran et al. 2009). 
Hopefully, international efforts may answer this important 
question, since the fast-track methodology is becoming more 
popular (Malviya et al. 2011, McDonald et al. 2011) but with a 
lack of specific information on thromboprophylaxis regimens 
despite very low thromboembolic complications (Malviya et 
al. 2011, McDonald et al. 2011).
In conclusion, there is an urgent need for multicenter stud-
ies to assess the requirement for thromboprophylaxis in the 
context of fast-track THA and TKA.
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